Form 8-K

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

 

FORM 8-K

 

 

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

 

Date of Report (Date of earliest event reported) February 11, 2004

 

 

ALEXION PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware   0-27756   13-3648318

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

 

352 Knotter Drive, Cheshire, CT   06410
(Address of Principal Executive Offices)   (Zip Code)

 

 

Registrant’s telephone number, including area code: (203) 272-2596

 

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Item 5.    Other Events and Regulation FD Disclosure

 

On February 11, 2004, the Company announced the appointment of Carsten Boess as Vice President and Chief Financial Officer, a newly created position. A copy of the press release issued by the Company relating thereto is filed herewith as Exhibit 99.1.

 

 

Item 7.    Financial Statements and Exhibits.

 

  (c) Exhibits.

 

  99.1 Press Release dated February 11, 2004.

 

2

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

     ALEXION PHARMACEUTICALS, INC.

Date: February 11, 2004

    By:    /S/    DAVID W. KEISER
         
     Name:    David W. Keiser
     Title:    President and Chief Operating Officer

 

3